Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling
about
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical CorrelatesDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned ratsVU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo EfficacyGRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domainMaladaptive striatal plasticity in L-DOPA-induced dyskinesia.Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.Development of allosteric modulators of GPCRs for treatment of CNS disordersMetabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.Therapeutic potential of metabotropic glutamate receptor modulators.Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson ModelMetabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Glutamate receptors as therapeutic targets for Parkinson's disease.Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsTherapeutic potential of targeting glutamate receptors in Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseasePharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.G protein-coupled receptor kinases as regulators of dopamine receptor functions.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic ratsMetabotropic glutamate receptors for Parkinson's disease therapy.Dopamine-Induced Changes in Gαolf Protein Levels in Striatonigral and Striatopallidal Medium Spiny Neurons Underlie the Genesis of l-DOPA-Induced Dyskinesia in Parkinsonian Mice
P2860
Q26852311-E6F67436-681E-497F-850E-0BDAB13325C5Q27021464-EF95A39E-754E-4F47-A962-696D1CBAA2BEQ28482094-382AB993-EA61-4B5B-9095-273C152CD588Q30366876-56503AD0-618E-4D9E-A956-F024CD186851Q30653115-33B4E569-760B-49BD-BD90-6EF5F6C63B02Q34094008-369D8A64-069C-4842-BE23-39CCD44FF3DFQ34116613-F9CFE86A-E504-40DE-AB8C-6C249EB9110AQ34373958-A14A7AD6-00F9-409E-91BD-B16EC549F3BBQ35065682-FDD8CAA9-D179-44E9-90CC-DA94716B0714Q35070472-578390AF-D404-401C-8F10-14594E4F9334Q35124773-159F209D-03FE-4081-9197-FC58D012D0F6Q35492255-AD853FFE-E381-4298-9A36-5858D230BE62Q35614156-EC381CEB-1BEF-4547-A4DC-5C0E89BBA1C6Q35738538-068E6CFC-14E4-4BD0-97D2-D3E8E4373E78Q35778704-79779BBA-DEFE-43CB-9045-45AE48DA1F2BQ37208065-2E63DE2D-A7F3-485B-857D-B3E1DC520C6DQ37384351-85E32229-29E5-4EA0-AE23-53B03297E50AQ37506507-BA12F351-E598-49C3-B63D-6150CE28436AQ37585401-5855BFE7-A7DE-4934-872A-74A1326C8CCAQ37714802-4428F33E-7E52-4BB6-8632-08DD24CEE724Q37782115-677AF668-0192-474C-92A0-8E7F6DEDDC48Q37809494-2E8C91C5-555F-4FC3-B192-8A49CB881F3EQ37924629-F59A6E04-F631-42B4-9031-99D7633D8F64Q37925513-F01EC2C7-12D6-4936-9CCD-2F7167D318DEQ37974709-F6D71BCA-FFE4-413C-8200-26DC9DDE0D8AQ38056852-DFC25AA4-2CB0-4C14-8738-38042B128ED0Q38092819-440350C6-4C71-4884-BE1D-CF1EC2761CA6Q38156760-4AB839B4-88C4-4F18-959E-25A73C3B88EEQ38190016-C8AC4257-D2EF-4454-AF89-62678CBD7E59Q38218083-3E493F21-156C-4C21-BFCC-9B53B834D7C2Q38262418-FB2C7BC1-A63B-44C4-854E-A382977F2650Q38285126-687A0C6B-0016-464B-974E-49471B8D5716Q38355582-6343398C-DE6F-486E-A001-E559640C27E1Q38658203-01461022-C798-4831-A7BD-89CBA911BF9AQ38660240-8C459626-262F-4493-B805-7F8EC69AE038Q38834292-FF3EF2FD-5756-4CE5-990F-3B89BF9A6D7BQ38951947-CA39FF4E-4121-44C0-A9B6-C582A66A6CC7Q40789803-2B5C7408-2B43-4A48-8C7B-B422877E8116Q41818450-9F5AD51C-D8EC-490B-97A5-FE59F9BF619DQ42322627-E767CE4D-C5A3-4784-B80D-060D5C5D55A0
P2860
Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacological modulation of ...... and striatal nuclear signaling
@ast
Pharmacological modulation of ...... and striatal nuclear signaling
@en
type
label
Pharmacological modulation of ...... and striatal nuclear signaling
@ast
Pharmacological modulation of ...... and striatal nuclear signaling
@en
prefLabel
Pharmacological modulation of ...... and striatal nuclear signaling
@ast
Pharmacological modulation of ...... and striatal nuclear signaling
@en
P2093
P2860
P921
P356
P1476
Pharmacological modulation of ...... and striatal nuclear signaling
@en
P2093
Alessandra Recchia
Andrzej Dekundy
Flora Mela
M Angela Cenci
Wojciech Danysz
P2860
P304
P356
10.1124/JPET.108.150425
P407
P577
2009-04-08T00:00:00Z